INOVASIA Study: A Multicenter Randomized Clinical Trial of Pravastatin to Prevent Preeclampsia in High-Risk Patients

Muhammad Ilham Aldika Akbar, Muhammad Alamsyah Azis, Deviana Soraya Riu, Ellen Wawengkang, Ernawati Ernawati, Muhammad Adrianes Bachnas, Sri Sulistyowati, Erry Gumilar Dachlan, Johanes Cornelius Mose, Gus Dekker

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)

Abstract

Objective Our objective was to determine if treatment with pravastatin prevents preeclampsia in pregnant patients at risk of preeclampsia. Material and Methods The study was performed in four major tertiary hospitals in Surabaya, Bandung, and Makassar between 2017 and 2021. Pregnant women at high risk of developing preeclampsia were recruited and randomized into an intervention group and control group. The control group received low-dose aspirin (80 mg) and calcium (1 g) daily, while the intervention group received additional pravastatin (20 mg twice daily) starting from 14 to 20 weeks' gestation until delivery. The pregnancy was followed until delivery, and the clinical data were collected. The primary outcome was the occurrence of preeclampsia. Result A total of 173 people participated in this study, including 86 in the control group and 87 in the pravastatin group. The pravastatin group had a significantly lower rate of preterm preeclampsia (13.8 vs. 26.7%; p = 0.034; odds ratio [OR] = 0.034, 95% confidence interval [CI] = 0.202-0.905) and preterm birth (16.1 vs. 36%; p = 0.003; OR = 0.340, 95% CI = 0.165-0.7), mostly indicated preterm birth. Preeclampsia occurred later in the pravastatin group than in the control group (36.39 + 2.32 vs. 34.89 + 3.38 weeks, p = 0.048). Overall, the pravastatin group showed better perinatal outcomes. Neonates with low Apgar scores (<7) at 1 minute (5.7 vs. 25.6%, p = 0.000) and 5 minutes (2.3 vs. 25.6%, p = 0.028) were significantly less common in the pravastatin group. Additionally, the rate of low birthweight babies (<2,500 g) was lower in the pravastatin group (27.6 vs. 40.7%; p = 0.069). Conclusion Pravastatin (20 mg bid) significantly reduces the risk of preterm preeclampsia and preterm birth in women at a high risk of developing preeclampsia. Key Points This is an open-label multicenter RCT to evaluate pravastatin effect to prevent preeclampsia. Pravastatin significantly reduces the risk of preterm preeclampsia (PE) and preterm birth in high risk PE women. Pravastatin had a beneficial effect on perinatal outcomes, including Apgar scores and birth weight.

Original languageEnglish
JournalAmerican Journal of Perinatology
DOIs
Publication statusAccepted/In press - 2022

Keywords

  • maternal outcomes
  • perinatal outcomes
  • pravastatin
  • preeclampsia
  • short-term health

Fingerprint

Dive into the research topics of 'INOVASIA Study: A Multicenter Randomized Clinical Trial of Pravastatin to Prevent Preeclampsia in High-Risk Patients'. Together they form a unique fingerprint.

Cite this